Leap Therapeutics (NASDAQ:LPTX) Trading 0.6% Higher

Leap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) shares traded up 0.6% on Friday . The company traded as high as $3.28 and last traded at $3.19. 334,593 shares changed hands during trading, an increase of 8% from the average session volume of 308,469 shares. The stock had previously closed at $3.17.

Analysts Set New Price Targets

A number of research analysts have recently commented on LPTX shares. Robert W. Baird decreased their price objective on shares of Leap Therapeutics from $11.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, March 19th. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Leap Therapeutics in a report on Tuesday, March 19th.

Leap Therapeutics Stock Up 0.6 %

The company's fifty day moving average price is $2.77 and its 200 day moving average price is $2.76. The company has a market capitalization of $81.66 million, a P/E ratio of -0.63 and a beta of 0.54.

Leap Therapeutics (NASDAQ:LPTX - Get Free Report) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.10. Research analysts predict that Leap Therapeutics, Inc. will post -2.08 earnings per share for the current fiscal year.

Institutional Trading of Leap Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. 683 Capital Management LLC grew its stake in shares of Leap Therapeutics by 60.7% during the third quarter. 683 Capital Management LLC now owns 490,000 shares of the company's stock worth $676,000 after buying an additional 185,001 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Leap Therapeutics during the third quarter worth $489,000. Key Client Fiduciary Advisors LLC grew its stake in shares of Leap Therapeutics by 8.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 233,018 shares of the company's stock worth $620,000 after buying an additional 18,408 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in shares of Leap Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 46,994 shares of the company's stock worth $65,000 after buying an additional 23,497 shares during the last quarter. Institutional investors own 30.46% of the company's stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.